Key result
Redo-mitral valve replacement carries ~12% in-hospital mortality, predicted by reduced LVEF and structural valve degeneration.
Observational (n=96)
No
Redo-mitral valve replacement carries an 11.5% in-hospital mortality risk, which is significantly increased in patients with LVEF <50%, structural valve degeneration, and longer operative times.
High redo-MVR mortality warrants cautious patient selection; observational data leaves open whether optimized timing or techniques improve outcomes.
The operative mortality associated with redo heart valve surgery is higher than that of the primary operation 1. this study aimed to scrutinize the overall hospital morbidity and mortality of adult patients undergoing redo-mitral valve replacement (redo-MVR) at our hospital and identify predictors of operative death and prolonged hospital stay.
No takes yet. Share an insight, caveat, or question.
Abd‐ElGawad et al. (2017) conducted an observational in Redo mitral valve replacement (n=96). Redo mitral valve replacement (redo-MVR) was evaluated on In-hospital mortality. Redo-mitral valve replacement in adult patients was associated with an in-hospital mortality of 11.5%, which was significantly predicted by left ventricular ejection fraction <50% and structural valve degeneration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: